Keryx Biopharmaceuticals, Inc. (KERX) Drug Fails FDA Trial But CEO States It’s Not The End Of Keryx
Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) had disappointing news on March 7, 2008. They announced that their Sulonex SUN-MICRO Phase 3 clinical trial failed to meet the primary objective of the study. This Phase 3 trial was for the treatment of diabetic nephropathy. Michael S. Weiss, the Company's Chairman and Chief Executive Officer, commented, "We are all very disappointed with the outcome of this study. While this represents the end of one chapter for Keryx, it is not the end of Keryx. Drug development is inherently risky and, accordingly, we have spent the last several years building what we believe to…